<DOC>
	<DOC>NCT00443209</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants. The primary hypothesis of this study is that telcagepant is well tolerated in the long-term treatment of acute migraine in adult participants.</brief_summary>
	<brief_title>Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>At least 1 year history of migraine (with or without aura) Females of child bearing potential must use acceptable contraception throughout trial In general good health based on screening assessment Pregnant/breastfeeding (or is a female expecting to conceive during study period) History or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (HIV) disease Major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) History of gastric, or small intestinal surgery, or has a disease that causes malabsorption History of cancer within the last 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>